Fewer Antibodies Against PRX-102 Than Fabrazyme Likely, Trial Data Suggest
Fabry disease patients may naturally have higher levels of neutralizing antibodies against Fabrazyme (agalsidase beta) than against Protalix BioTherapeutics‘ investigational PRX-102 (pegunigalsidase alfa), BALANCE Phase 3 trial data suggest. As antibodies can limit the effectiveness of enzyme replacement therapies, developing less of them suggests that…